Cargando…

Avelumab demonstrates promise in advanced NSCLC

Detalles Bibliográficos
Autores principales:	Marciscano, Ariel E., Gulley, James L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732688/ https://www.ncbi.nlm.nih.gov/pubmed/29262522 http://dx.doi.org/10.18632/oncotarget.22418

Ejemplares similares

Product review: avelumab, an anti-PD-L1 antibody
por: Collins, Julie M., et al.
Publicado: (2018)

Avelumab in Combination With Cetuximab and Chemotherapy as First-Line Treatment for Patients With Advanced Squamous NSCLC
por: Andric, Zoran, et al.
Publicado: (2023)

The role of avelumab in advanced urothelial carcinoma in the context of a dynamic treatment landscape
por: Koshkin, Vadim S., et al.
Publicado: (2019)

Avelumab plus axitinib vs. sunitinib for advanced renal-cell carcinoma
por: Zhang, Yue, et al.
Publicado: (2019)

Efficacy and immune-related adverse event associations in avelumab-treated patients
por: Kelly, Karen, et al.
Publicado: (2020)

Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab
por: Martini, Giulia, et al.
Publicado: (2022)

Diffuse lichen planus-like keratoses and clinical pseudo-progression associated with avelumab treatment for Merkel cell carcinoma, a case report
por: Cardis, Michael A., et al.
Publicado: (2019)

Long-term avelumab in advanced non-small-cell lung cancer: summaries and post hoc analyses from JAVELIN Solid Tumor
por: Hrinczenko, Borys, et al.
Publicado: (2022)

A review of avelumab in locally advanced and metastatic bladder cancer
por: Rao, Arpit, et al.
Publicado: (2019)

Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma
por: Rajan, Arun, et al.
Publicado: (2019)

Avelumab in newly diagnosed glioblastoma
por: Jacques, Francois H, et al.
Publicado: (2021)

Avelumab in Men With Metastatic Castration-Resistant Prostate Cancer, Enriched for Patients Treated Previously With a Therapeutic Cancer Vaccine
por: Madan, Ravi A., et al.
Publicado: (2023)

Avelumab for advanced Merkel cell carcinoma in the Netherlands: a real-world cohort
por: Levy, Sonja, et al.
Publicado: (2020)

Evaluation of the potential for QTc prolongation with avelumab
por: Vugmeyster, Yulia, et al.
Publicado: (2019)

Clinical Evaluation of Avelumab in the Treatment of Advanced Urothelial Carcinoma: Focus on Patient Selection and Outcomes
por: Ten Eyck, Jennifer E, et al.
Publicado: (2022)

Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial
por: Le Tourneau, Christophe, et al.
Publicado: (2018)

Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody
por: Donahue, Renee N., et al.
Publicado: (2017)

First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma
por: Strauss, Julius, et al.
Publicado: (2023)

Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial
por: Keilholz, Ulrich, et al.
Publicado: (2019)

Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials
por: Kelly, Karen, et al.
Publicado: (2018)

Promising Advances for Imaging Lung Macrophage Recruitment
por: Chen, Delphine L.
Publicado: (2020)

Immunotherapy in Merkel cell carcinoma: role of Avelumab
por: Palla, Amruth R, et al.
Publicado: (2018)

Diffuse Alveolar Hemorrhage With Avelumab Maintenance Therapy
por: Li, Si, et al.
Publicado: (2021)

Avelumab: clinical trial innovation and collaboration to advance anti-PD-L1 immunotherapy
por: Chin, K., et al.
Publicado: (2017)

Avelumab for Advanced Merkel Cell Carcinoma: Global Real-World Data on Patient Response and Survival
por: Lohray, Rishabh, et al.
Publicado: (2023)

Second-line avelumab in platinum-treated non-small cell lung cancer patients: comment on the JAVELIN Lung 200 clinical trial
por: Rocco, Danilo, et al.
Publicado: (2019)

Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: results from a phase Ib cohort of the JAVELIN Solid Tumor study
por: Verschraegen, Claire F, et al.
Publicado: (2020)

Placing a Cancer Diagnosis in Clinical Context: Applying Functional Trajectories to Advanced NSCLC
por: Hamann, Heidi A., et al.
Publicado: (2022)

Evolutionary perspectives on human infectious diseases: Challenges, advances, and promises
por: Echaubard, Pierre, et al.
Publicado: (2018)

Cost Effectiveness of Avelumab for Metastatic Merkel Cell Carcinoma
por: Bullement, Ash, et al.
Publicado: (2019)

Avelumab-induced Pneumonitis in Metastatic Merkel Cell Carcinoma
por: Morimoto, Toshiki, et al.
Publicado: (2022)

Avelumab first-line maintenance treatment for advanced urothelial carcinoma: review of evidence to guide clinical practice
por: Grivas, P., et al.
Publicado: (2023)

Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial
por: Vaishampayan, Ulka, et al.
Publicado: (2019)

Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial
por: Yap, Timothy A., et al.
Publicado: (2022)

Role of noninvasive molecular imaging in determining response
por: Marciscano, Ariel E., et al.
Publicado: (2018)

M7824: A promising new strategy to combat cancer immune evasion
por: Gatti-Mays, Margaret E., et al.
Publicado: (2018)

Avelumab-Induced Scleroderma in a Patient with Metastatic Squamous Cell Carcinoma of the Lung
por: Dobrzynski, Jeffrey L., et al.
Publicado: (2022)

Short-course radiation followed by mFOLFOX-6 plus avelumab for locally-advanced rectal adenocarcinoma
por: Shamseddine, Ali, et al.
Publicado: (2020)

Avelumab First-Line Maintenance Treatment in Advanced Bladder Cancer: Practical Implementation Steps for Infusion Nurses
por: Wood, Laura S., et al.
Publicado: (2022)

Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study
por: Apolo, Andrea B., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_agbl2c61ldn2tqtntp2ejs47hn